Vertex Pharmaceuticals (VRTX) reported Q4 non-GAAP net income late Monday of $3.98 per diluted share, down from $4.20 a year earlier.
Analysts polled by FactSet expected $4.02.
Product revenue for the quarter ended Dec. 31 was $2.91 billion, up from $2.52 billion a year earlier.
Analysts surveyed by FactSet forecast $2.78 billion.
The biotech firm expects fiscal 2025 revenue of $11.75 billion to $12 billion. Analysts polled by FactSet are looking for $11.84 billion.
Shares of Vertex Pharmaceuticals were up 1.2% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。